SAN FRANCISCO, Feb. 02, 2024 (GLOBE NEWSWIRE) Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted
SAN FRANCISCO, Feb. 02, 2024 Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for.
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer models Initiating IND-enabling studies with goal.
SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies
Palazestrant in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile.